RxDoctor Payments DataLook up a doctor →

Robert Winter, MD

Family Medicine · Newark, DENPI 1932279007

Payments from drug & device makers

$12,057in general payments, 2019–2025

Across 719 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Pfizer$901
  • Astellas Pharma US Inc$874
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$11,88299%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,057 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$188,502
Medicare patients
617
Services billed
1,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide99$132,152
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$63,354
JanuviaSitagliptin Phosphate38$53,542
JardianceEmpagliflozin39$40,606
OzempicSemaglutide16$35,171
EliquisApixaban32$34,381
XareltoRivaroxaban28$33,454
OxycontinOxycodone Hcl38$29,349
TrulicityDulaglutide13$28,413
LinzessLinaclotide14$19,191
MyrbetriqMirabegron14$18,251
Fentanyl47$13,010
VascepaIcosapent Ethyl14$10,942
Breo ElliptaFluticasone/Vilanterol14$9,434
Atorvastatin Calcium450$7,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,025$160,566112 claims
GSKTrelegy Ellipta, Breo Ellipta$1,166$72,78881 claims
MerckJanuvia$552$53,54238 claims
Boehringer IngelheimJardiance$215$40,60639 claims
Novo NordiskOzempic$602$35,17116 claims
PfizerEliquis$901$34,38132 claims
Johnson & JohnsonXarelto$246$33,45428 claims
AbbVieLinzess, Synthroid$1,639$23,04957 claims
Astellas Pharma US IncMyrbetriq$874$18,25114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.

Other family medicine in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →